涨停_老虎社区_美港股上老虎 - 老虎社区

点赞
评论
收藏

tetehao红茶
2021-08-21

涨停

南京医药(600713.SH)上半年归母净利润同比增长28.76%至2.22亿元

智通财经APP讯，南京医药发布2021年半年度报告，该公司期内营业收入218.97亿元，同比增长19.84%。归属于上市公司股东的净利润2.22亿元，同比增长28.76%。基本每股收益0.213元。报告期内，营业收入变动主要是公司报告期营业收入较上期增加主要系公司本期销售增长所致。

南京医药(600713.SH)上半年归母净利润同比增长28.76%至2.22亿元

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

点赞

举报

评论

推荐
最新

empty

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":836236838,"tweetId":"836236838","gmtCreate":1629497711524,"gmtModify":1629497711524,"author":{"id":3534470103714641,"idStr":"3534470103714641","authorId":3534470103714641,"authorIdStr":"3534470103714641","name":"tetehao红茶","avatar":"https://static.tigerbbs.com/0e0e0b8c1a6d1c31e25f5e6875d70445","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>涨停</p></body></html>","htmlText":"<html><head></head><body><p>涨停</p></body></html>","text":"涨停","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/836236838","repostId":2160715853,"repostType":2,"repost":{"id":"2160715853","kind":"news","pubTimestamp":1629450023,"share":"https://www.laohu8.com/m/news/2160715853?lang=&edition=full","pubTime":"2021-08-20 17:00","market":"hk","language":"zh","title":"南京医药(600713.SH)上半年归母净利润同比增长28.76%至2.22亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2160715853","media":"智通财经","summary":"智通财经APP讯，南京医药 发布2021年半年度报告，该公司期内营业收入218.97亿元，同比增长19.84%。归属于上市公司股东的净利润2.22亿元，同比增长28.76%。基本每股收益0.213元。报告期内，营业收入变动主要是公司报告期营业收入较上期增加主要系公司本期销售增长所致。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600713\">南京医药</a>(600713.SH)发布2021年半年度报告，该公司期内营业收入218.97亿元，同比增长19.84%。归属于上市公司股东的净利润2.22亿元，同比增长28.76%。归属于上市公司股东的扣除非经常性损益的净利润2.2亿元，同比增长69.29%。基本每股收益0.213元。</p><p>2021年上半年，公司坚持疫情防控和经营发展“两手抓”，一方面根据南京市政府及国资控股股东的部署要求，全力做好疫情防控物资保供及常态化疫情防控工作;另一方面积极应对行业“白热化”的竞争形势，主营业务保持稳中有进势头，各项目标任务继续扎实有序推进。</p><p>报告期内，营业收入变动主要是公司报告期营业收入较上期增加主要系公司本期销售增长所致。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>南京医药(600713.SH)上半年归母净利润同比增长28.76%至2.22亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n南京医药(600713.SH)上半年归母净利润同比增长28.76%至2.22亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 17:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/540152.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，南京医药(600713.SH)发布2021年半年度报告，该公司期内营业收入218.97亿元，同比增长19.84%。归属于上市公司股东的净利润2.22亿元，同比增长28.76%。归属于上市公司股东的扣除非经常性损益的净利润2.2亿元，同比增长69.29%。基本每股收益0.213元。2021年上半年，公司坚持疫情防控和经营发展“两手抓”，一方面根据南京市政府及国资控股股东的部署要求，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/540152.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e0ab8365ea89ee143187cbf51d23ba8f","relate_stocks":{"600713":"南京医药"},"source_url":"http://www.zhitongcaijing.com/content/detail/540152.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160715853","content_text":"智通财经APP讯，南京医药(600713.SH)发布2021年半年度报告，该公司期内营业收入218.97亿元，同比增长19.84%。归属于上市公司股东的净利润2.22亿元，同比增长28.76%。归属于上市公司股东的扣除非经常性损益的净利润2.2亿元，同比增长69.29%。基本每股收益0.213元。2021年上半年，公司坚持疫情防控和经营发展“两手抓”，一方面根据南京市政府及国资控股股东的部署要求，全力做好疫情防控物资保供及常态化疫情防控工作;另一方面积极应对行业“白热化”的竞争形势，主营业务保持稳中有进势头，各项目标任务继续扎实有序推进。报告期内，营业收入变动主要是公司报告期营业收入较上期增加主要系公司本期销售增长所致。","news_type":1,"symbols_score_info":{"600713":1}},"isVote":1,"tweetType":1,"viewCount":3047,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}